GoAI
Get started
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc.

SABS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.78

+$0.08 · +2.16%

Aug 21, 4:00 PM ET

Pre-market

$3.90

+$0.12 · +3.17%

Aug 24, 4:34 AM ET

SABS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

33

Expensive

Momentum

44

Neutral

Sentiment

61

Bullish

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Samuel J. Reich
Listed since
Feb 9, 2021
Employees
86

Market position

Day range

Current $3.78

52-week range

Current $3.78

Open
$3.70
Previous close
$3.70
Volume
195.67K
0.26× average
Average volume
746.97K
Average daily volume
Market cap
343.93M USD
Beta
0.53
Market reference 1
50-day average
$3.7331
+1.26% above average
200-day average
$3.7945
-0.38% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
67.67M USD
P/E (TTM)
3.05×
P/B (TTM)
1.4×
P/S (TTM)
0×
EV / EBITDA
4.08×
Earnings yield
18.38%
Free cash flow yield
-63.29%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
8.76%
Return on assets
7.68%
Return on invested capital
-30.02%

Financial health

Debt / equity
0.02×
Current ratio
9.46×
Altman Z-score
8.23
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends431%-905%-2242%-3579%Gross margin, FY2021: 97.28%Gross margin, FY2022: 86.23%Gross margin, FY2023: -67.26%Gross margin, FY2024: -262.41%Operating margin, FY2021: -22.00%Operating margin, FY2022: -120.98%Operating margin, FY2023: -1700.54%Operating margin, FY2024: -3244.87%Net margin, FY2021: -28.16%Net margin, FY2022: -78.40%Net margin, FY2023: -1884.50%Net margin, FY2024: -2579.03%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 97.28%. Gross margin FY2022 86.23%. Gross margin FY2023 -67.26%. Gross margin FY2024 -262.41%. Operating margin FY2021 -22.00%. Operating margin FY2022 -120.98%. Operating margin FY2023 -1700.54%. Operating margin FY2024 -3244.87%. Net margin FY2021 -28.16%. Net margin FY2022 -78.40%. Net margin FY2023 -1884.50%. Net margin FY2024 -2579.03%.

Income trends

Revenue

1.32M USD-40.94%

Operating income

−48.95M USD-14.08%

Net income

13.27M USD+47.38M USD
Income trends across reported periods71.86M USD27.93M USD−16M USD−59.94M USDRevenue, FY2021: 60.88M USDRevenue, FY2022: 23.9M USDRevenue, FY2023: 2.24M USDRevenue, FY2024: 1.32M USDOperating income, FY2021: −13.39M USDOperating income, FY2022: −28.92M USDOperating income, FY2023: −38.08M USDOperating income, FY2024: −42.91M USDOperating income, FY2025: −48.95M USDNet income, FY2021: −17.15M USDNet income, FY2022: −18.74M USDNet income, FY2023: −42.19M USDNet income, FY2024: −34.11M USDNet income, FY2025: 13.27M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 60.88M USD. Revenue FY2022 23.9M USD. Revenue FY2023 2.24M USD. Revenue FY2024 1.32M USD. Operating income FY2021 −13.39M USD. Operating income FY2022 −28.92M USD. Operating income FY2023 −38.08M USD. Operating income FY2024 −42.91M USD. Operating income FY2025 −48.95M USD. Net income FY2021 −17.15M USD. Net income FY2022 −18.74M USD. Net income FY2023 −42.19M USD. Net income FY2024 −34.11M USD. Net income FY2025 13.27M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—1.32M USD2.24M USD23.9M USD60.88M USD
Cost of goods sold3.08M USD4.79M USD3.75M USD3.29M USD1.65M USD
Gross profit−3.08M USD−3.47M USD−1.51M USD20.61M USD59.22M USD
Research and development34.35M USD30.16M USD16.52M USD36.44M USD57.18M USD
Selling, general, and administrative14.6M USD9.28M USD23.8M USD16.38M USD17.09M USD
Operating expenses45.87M USD39.44M USD36.57M USD49.53M USD72.62M USD
Interest income1.43M USD1.29M USD584.97K USD71.07K USD23.12K USD
Interest expense240.66K USD318.4K USD315.28K USD301.58K USD294.46K USD
Depreciation and amortization3.08M USD4.79M USD3.75M USD3.29M USD1.65M USD
Operating income−48.95M USD−42.91M USD−38.08M USD−28.92M USD−13.39M USD
Net income13.27M USD−34.11M USD−42.19M USD−18.74M USD−17.15M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-51.53%
11 comparable reports
Latest EPS result
-0.28
Estimate -0.28 · Beat by 1.06%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.14-0.53-0.92-1.32Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 28, 2025: actual -1.23, estimate -1.16, surprise -6.03%, Miss. Q2 2025, reported May 9, 2025: actual -0.56, estimate -1, surprise +44.00%, Beat. Q3 2025, reported Aug 7, 2025: actual -1.09, estimate -0.82, surprise -32.93%, Miss. Q4 2025, reported Nov 14, 2025: actual -0.21, estimate -0.59, surprise +64.41%, Beat. Q1 2026, reported Mar 9, 2026: actual -0.46, estimate -0.16, surprise -187.50%, Miss. Q2 2026, reported May 12, 2026: actual -0.35, estimate -0.2, surprise -75.00%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.28, estimate -0.283, surprise +1.06%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.27, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates130K112.78K95.55K78.33KQ1 '25MissQ2 '25EstimateQ3 '25EstimateQ4 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 28, 2025: actual 100K USD, estimate 120K USD, surprise -16.67%, Miss. Q2 2025, reported May 9, 2025: actual —, estimate 125K USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 7, 2025: actual —, estimate 83.33K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual —, estimate 100K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 9, 2026: actual —, estimate 100K USD, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual —, estimate 125K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual —, estimate 125K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 13, 2026: actual —, estimate 125K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$11.33

199.74% upside
Past 12 months12-month forecastHigh $13.00Average $11.33Low $10.00

Recent analyst actions

6 institutions
Leerink PartnersmaintainOutperform
Rodman & RenshawmaintainBuy
OppenheimermaintainOutperform
Ladenburg ThalmanndowngradeBuyNeutral

SABS news

marketbeat.com

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB Biotherapeutics NASDAQ: SABS said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with…

Read source
globenewswire.com

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027…

Read source
defenseworld.net

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat.com reports. One…

Read source
globenewswire.com

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical…

Read source
globenewswire.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D Data will highlight deeper mechanistic insights and long-term…

Read source

Corporate actions

Corporate action history

Stock split

Effective Jan 5, 2024

1:10

SABS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SABS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
8.07M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.84M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.31M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
1.41M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
873.21K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
560.43K
Weight
0.04%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Simplify Propel Opportunities ETF logoSimplify Propel Opportunities ETFSURI
Market value
396.33K
Weight
0.47%
AUM
85.05M USD
Expense ratio
2.82%
Price / 1D
$19.8186-0.20%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
361.19K
Weight
0.01%
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%

Continue in GoAI

Research SABS

research.disclaimer